Galaxy Therapeutics Secures CE Mark for SEAL System
Milpitas, California, August 4, 2026 Galaxy Therapeutics has announced that its SEALâ„¢ Embolization System has received CE Mark certification...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Milpitas, California, August 4, 2026 Galaxy Therapeutics has announced that its SEALâ„¢ Embolization System has received CE Mark certification...
Maple Grove, Minn., July 22, 2026 Serenity Medical announced new four- to five-year clinical data demonstrating the long-term effectiveness...
LOS GATOS, Calif., April 13, 2026 Radical Catheter Technologies has received U.S. Food and Drug Administration (FDA) 510(k) clearance...
